Evidence map›Paper›PMID 33753768›Full record

ArticleScientific reports2021

Author Correction: Mir142 loss unlocks IDH2

A Marshall, J Kasturiarachchi, P Datta, Y Guo, E Deltcheva, C James, J Brown, G May, N Anandagoda, I Jackson and 10 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

A Marshall *UCL Cancer Institute, University College London, London, UK.
J Kasturiarachchi *UCL Cancer Institute, University College London, London, UK.
P DattaUCL Cancer Institute, University College London, London, UK.
Y GuoUCL Cancer Institute, University College London, London, UK.
E DeltchevaUCL Cancer Institute, University College London, London, UK.
C JamesUCL Cancer Institute, University College London, London, UK.
J BrownUCL Cancer Institute, University College London, London, UK.
G MayUCL Cancer Institute, University College London, London, UK.
N AnandagodaSchool of Immunology and Microbial Sciences, King's College London, London, UK.
I JacksonSchool of Immunology and Microbial Sciences, King's College London, London, UK.
J K HowardSchool of Life Course Sciences, King's College London, London, UK.
E GhazalyCentre for Haemato‑Oncology, Barts Cancer Institute, Queen Mary University of London, London, Queen, UK.
S BrooksUCL Cancer Institute, University College London, London, UK.
A KhwajaUCL Cancer Institute, University College London, London, UK.
M ArakiInstitute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
K ArakiInstitute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
D LinchUCL Cancer Institute, University College London, London, UK.
G M LordFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
T EnverUCL Cancer Institute, University College London, London, UK.
R NimmoUCL Cancer Institute, University College London, London, UK. r.nimmo@oxb.com.
CRUK Lung Cancer Centre of Excellence · GBUniversity College London · GBKing's College London · GBKumamoto University · JPQueen Mary University of London · GBUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33753768
PMCPMC7985147
OpenAlexW3136955425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.